BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC announced the FDA’s Orphan Drug Designation for BVX001, aimed at treating Acute Myeloid Leukaemia, which promises financial benefits and market exclusivity. The company successfully completed an FDA INTERACT meeting, securing guidance for the investigational new drug application process. This marks a significant step towards addressing the unmet medical needs in AML treatment, with plans to present more data later in 2024.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
